AffyImmune Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- AffyImmune Therapeutics's estimated annual revenue is currently $2.6M per year.
- AffyImmune Therapeutics's estimated revenue per employee is $77,500
- AffyImmune Therapeutics's total funding is $28.9M.
Employee Data
- AffyImmune Therapeutics has 33 Employees.
- AffyImmune Therapeutics grew their employee count by 38% last year.
AffyImmune Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP CMC | Reveal Email/Phone |
2 | SVP, Head Clinical Development | Reveal Email/Phone |
3 | VP Clinical Operations | Reveal Email/Phone |
4 | SVP Operations and Business Development | Reveal Email/Phone |
5 | Head CMC | Reveal Email/Phone |
6 | CMC Logistics Manager | Reveal Email/Phone |
7 | Research Associate | Reveal Email/Phone |
8 | Senior Scientist | Reveal Email/Phone |
9 | Finance & Operations | Reveal Email/Phone |
10 | Senior Scientist | Reveal Email/Phone |
AffyImmune Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is AffyImmune Therapeutics?
Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first product, spares healthy cells through our unique affinity-tuning, enhancing its safety and efficacy. The initial indication for AIC100 is refractory thyroid cancer, which has a very poor prognosis and very few effective therapies. The antigen targeted by AIC100 is also overexpressed in a variety of additional cancers, including stomach, triple negative breast cancer and a number of others.
keywords:N/A
$28.9M
Total Funding
33
Number of Employees
$2.6M
Revenue (est)
38%
Employee Growth %
N/A
Valuation
N/A
Accelerator
AffyImmune Therapeutics News
NATICK, Mass., April 6, 2022 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track...
Other Companies in Natick
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.6M | 33 | 6% | $45M |
#2 | $6.2M | 34 | 3% | N/A |
#3 | $3.9M | 34 | N/A | N/A |
#4 | $7M | 35 | -3% | N/A |
#5 | $2.8M | 35 | 6% | N/A |